P/B
—
Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
$393.3M
Market Cap • 10/2/2026
2001
(25 years)
Founded
2002
(24 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
393,3M
EV
519,9M
EV/Revenue
0
EV/EBITDA
-33,4
EV/EBIT
-33,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,4%
Total Yield
-1,4%
Payout
0%
Retained Earnings
-446,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,1%
% Goodwill
0%
ROE
23,5%
ROIC
—
Growth
CAGR Op. Income 5Y
-11,2%
CAGR Net Income 5Y
0,9%
CAGR EPS 5Y
-2,6%
CAGR OCF 5Y
-9,4%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,1
Quick Ratio
0,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!